AgingResearch.NewsJoin free

Fucoidan-fv

Intervention

1 paper1 finding

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Cells1

Outcomes

1

Premature aging–associated molecular defects

downin human cells1

1 study

  1. Fucoidan-fv decreases premature aging–associated molecular defects in human cells.

    “pharmacologically mimicking the centenarian variants using SIRT6 activator Fucoidan-FV partially ameliorated premature aging–associated molecular defects in progeria fibroblasts.”

    Cellsprogeriafibroblast

    Rare centenarian SIRT6 variants elevate SIRT6 protein levels and resist cellular senescence

    bioRxiv (Cold Spring Harbor Laboratory)30 Sep 2025Preprint

Latest

Related